Met Life Investment Management, LLC Syndax Pharmaceuticals Inc Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

A detailed history of Met Life Investment Management, LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Met Life Investment Management, LLC holds 47,554 shares of SNDX stock, worth $758,486. This represents 0.01% of its overall portfolio holdings.

Number of Shares
47,554
Previous 47,554 -0.0%
Holding current value
$758,486
Previous $976,000 6.25%
% of portfolio
0.01%
Previous 0.01%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$18.82 - $23.79 $136,068 - $172,001
7,230 Added 17.93%
47,554 $976,000
Q1 2024

May 14, 2024
BUY
$19.71 - $24.57 $794,786 - $990,760
40,324 New
40,324 $959,000
Q3 2023

May 09, 2024
BUY
$14.52 - $21.77 $45,389 - $68,053
3,126 Added 9.88%
34,755 $504,000
Q2 2023

Apr 29, 2024
BUY
$19.35 - $22.31 $672,509 - $775,384
34,755 New
34,755 $727,000
Q2 2023

Aug 10, 2023
BUY
$19.35 - $22.31 $60,488 - $69,741
3,126 Added 9.88%
34,755 $727,000
Q1 2023

May 09, 2024
BUY
$20.66 - $28.98 $653,455 - $916,608
31,629 New
31,629 $668 Million
Q1 2023

May 15, 2023
BUY
$20.66 - $28.98 $76,483 - $107,283
3,702 Added 13.26%
31,629 $668,000
Q4 2022

May 10, 2024
BUY
$20.64 - $26.24 $18,534 - $23,563
898 Added 3.32%
27,927 $710,000
Q4 2022

Jun 14, 2023
SELL
$20.64 - $26.24 $76,409 - $97,140
-3,702 Reduced 11.7%
27,927 $710,000
Q4 2022

Mar 22, 2023
BUY
$20.64 - $26.24 $18,534 - $23,563
898 Added 3.32%
27,927 $710,000
Q4 2022

Feb 15, 2023
BUY
$20.64 - $26.24 $18,534 - $23,563
898 Added 3.32%
27,927 $710,000
Q3 2022

Jun 14, 2023
SELL
$18.51 - $24.79 $85,146 - $114,034
-4,600 Reduced 14.54%
27,029 $649,000
Q2 2022

Jun 20, 2023
SELL
$13.64 - $19.48 $62,744 - $89,608
-4,600 Reduced 14.54%
27,029 $520,000
Q1 2022

May 10, 2024
BUY
$14.84 - $22.15 $401,110 - $598,692
27,029 New
27,029 $469,000
Q1 2022

Jun 20, 2023
SELL
$14.84 - $22.15 $68,264 - $101,890
-4,600 Reduced 14.54%
27,029 $469,000
Q1 2022

Mar 22, 2023
BUY
$14.84 - $22.15 $148,043 - $220,968
9,976 Added 58.5%
27,029 $469,000
Q1 2022

May 12, 2022
BUY
$14.84 - $22.15 $148,043 - $220,968
9,976 Added 58.5%
27,029 $470,000
Q4 2021

Jun 21, 2023
SELL
$15.23 - $22.47 $221,992 - $327,522
-14,576 Reduced 46.08%
17,053 $373,000
Q3 2021

Jun 21, 2023
SELL
$13.87 - $19.8 $202,169 - $288,604
-14,576 Reduced 46.08%
17,053 $325,000
Q2 2021

May 17, 2024
BUY
$13.42 - $25.18 $78,345 - $147,000
5,838 Added 52.06%
17,053 $292,000
Q2 2021

Jun 21, 2023
SELL
$13.42 - $25.18 $195,609 - $367,023
-14,576 Reduced 46.08%
17,053 $292,000
Q2 2021

Mar 22, 2023
BUY
$13.42 - $25.18 $78,345 - $147,000
5,838 Added 52.06%
17,053 $292,000
Q2 2021

Aug 16, 2021
BUY
$13.42 - $25.18 $78,345 - $147,000
5,838 Added 52.06%
17,053 $293,000
Q1 2021

May 17, 2024
SELL
$19.28 - $24.59 $561,221 - $715,790
-29,109 Reduced 72.19%
11,215 $250,000
Q1 2021

Jun 26, 2023
SELL
$19.28 - $24.59 $393,581 - $501,980
-20,414 Reduced 64.54%
11,215 $251 Million
Q4 2020

Jun 22, 2023
SELL
$15.1 - $26.44 $308,251 - $539,746
-20,414 Reduced 64.54%
11,215 $249,000
Q3 2020

Jun 26, 2023
SELL
$13.39 - $17.48 $273,343 - $356,836
-20,414 Reduced 64.54%
11,215 $165,000
Q2 2020

May 24, 2024
SELL
$8.94 - $20.98 $260,234 - $610,706
-29,109 Reduced 72.19%
11,215 $166 Million
Q2 2020

Jun 26, 2023
SELL
$8.94 - $20.98 $182,501 - $428,285
-20,414 Reduced 64.54%
11,215 $166,000
Q1 2020

Jul 12, 2023
SELL
$6.65 - $12.03 $135,753 - $245,580
-20,414 Reduced 64.54%
11,215 $123,000
Q1 2020

Mar 22, 2023
SELL
$6.65 - $12.03 $111,134 - $201,045
-16,712 Reduced 59.84%
11,215 $123,000
Q1 2020

May 15, 2020
BUY
$6.65 - $12.03 $74,579 - $134,916
11,215 New
11,215 $123,000

Others Institutions Holding SNDX

# of Institutions
227
Shares Held
88.3M
Call Options Held
1.01M
Put Options Held
692K
View Full List

About Syndax Pharmaceuticals Inc

SNDX Quotes by TradingView
  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $902M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email